title

The catechol-O-methyltransferase inhibitor tolcapone modulates alcohol consumption and impulsive choice in alcohol use disorder | Psychopharmacology

charset

UTF-8

X-UA-Compatible

IE=edge

applicable-device

pc,mobile

viewport

width=device-width, initial-scale=1

og:url

https://link.springer.com/article/10.1007/s00213-020-05599-5

og:type

article

og:site_name

SpringerLink

og:title

The catechol-O-methyltransferase inhibitor tolcapone modulates alcohol consumption and impulsive choice in alcohol use disorder - Psychopharmacology

og:description

Rationale Individuals suffering from alcohol use disorder (AUD) demonstrate difficulty with decision-making and impulsivity that may be associated with impaired frontal cortical function. Therapeutics that enhance frontal dopamine tone could decrease impulsivity and in turn reduce alcohol consumption in individuals with AUD. Objectives To determine if the catechol-O-methyltransferase (COMT) inhibitor tolcapone can attenuate alcohol consumption in individuals with AUD and whether this attenuation correlates with tolcapone-induced changes in laboratory-based decision-making tasks. Methods We used daily self-report and a novel group laboratory bar task to assess the effects of randomized double-blind crossover administration of tolcapone (100 mg TID for 5 days) on alcohol consumption and laboratory tasks assessing impulsivity in 55 non-treatment-seeking subjects with AUD. Results Tolcapone significantly reduced self-reported alcohol consumption (t (54) = 2.05, p = 0.045). The effects of tolcapone on drinking significantly correlated with changes in impulsive decision-making, such that subjects with the greatest decrease in impulsive choice on tolcapone also reported the greatest decrease in alcohol consumption (r (45) = 0.40, p = 0.0053). We did not see effects of tolcapone on laboratory bar consumption. Adverse event (AE) reporting was low, with no significant difference in frequency or severity of AEs on tolcapone versus placebo. Conclusions These data demonstrate that COMT inhibitors such as tolcapone may be useful therapeutics for AUD. Trial registration ClinicalTrials.gov Identifier: NCT 02740582

twitter:site

@SpringerLink

twitter:card

summary_large_image

twitter:image:alt

Content cover image

twitter:title

The catechol-O-methyltransferase inhibitor tolcapone modulates alcohol consumption and impulsive choice in alcohol use disorder

twitter:description

Psychopharmacology - Individuals suffering from alcohol use disorder (AUD) demonstrate difficulty with decision-making and impulsivity that may be associated with impaired frontal cortical...

position

1

position

2

position

3

apple-touch-icon

/oscar-static/img/favicons/darwin/apple-touch-icon-6ef0829b9c.png

canonical

https://link.springer.com/article/10.1007/s00213-020-05599-5

icon

/oscar-static/img/favicons/darwin/android-chrome-192x192.png

icon

/oscar-static/img/favicons/darwin/favicon-32x32.png

icon

/oscar-static/img/favicons/darwin/favicon-16x16.png